Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).

Guidelines summarize and evaluate all currently available evidence on a particular issue with the aim of assisting physicians in selecting the best management strategy for an individual patient suffering from a given condition, taking into account the impact on outcome, as well as the risk–benefit ratio of particular diagnostic or therapeutic means. Guidelines are no substitutes for textbooks. The legal implications of medical guidelines have been discussed previously. A large number of Guidelines have been issued in recent years by the European Society of Cardiology (ESC) as well as by other societies and organizations. Because of the impact on clinical practice, quality criteria for development of guidelines have been established in order to make all decisions transparent to the user. The recommendations for formulating and issuing ESC Guidelines can be found on the ESC Web Site (http://www.escardio.org/guidelines-surveys/esc-guidelines/about/Pages/rules-writing.aspx). In brief, experts in the field are selected and undertake a comprehensive review of the published evidence for management and/or prevention of a given condition. A critical evaluation of diagnostic and therapeutic procedures is performed, including assessment of the risk–benefit ratio. Estimates of expected health outcomes for larger societies are included, where data exist. The level of evidence and the strength of recommendation of particular treatment options are weighed and graded according to pre-defined scales, as outlined in Tables 1 and 2 . View this table: Table 1 Classes of recommendations View this table: Table 2 Levels of evidence The experts of the writing panels have provided disclosure statements of all relationships they may have that might be perceived as real or potential sources of conflicts of interest. These disclosure forms are kept on file at the European Heart House, headquarters of the ESC. Any changes in conflict of interest that arise during the writing period must be notified to the ESC. The Task Force report received its entire financial support from …

[1]  D. Serr,et al.  PROPRANOLOL FOR THE TREATMENT OF HYPERTENSION IN PREGNANCY , 1978, British journal of obstetrics and gynaecology.

[2]  G. Klein,et al.  Acceleration of the Ventricular Response During Atrial Fibrillation in the Wolff‐Parkinson‐White Syndrome After Verapamil , 1982, Circulation.

[3]  R. Coleman,et al.  Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction. , 1986, The American journal of cardiology.

[4]  L. E. Peterson,et al.  Disopyramide in the maintenance of sinus rhythm after electroconversion of atrial fibrillation. A placebo-controlled one-year follow-up study. , 1988, European heart journal.

[5]  I. V. Van Gelder,et al.  Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter. , 1989, The American journal of cardiology.

[6]  H L Greene,et al.  Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. , 1991, The New England journal of medicine.

[7]  J. Boineau,et al.  Successful surgical treatment of atrial fibrillation. Review and clinical update. , 1991, JAMA.

[8]  J. Cox,et al.  Successful surgical treatment for atrial fibrillation , 1992 .

[9]  P C Deedwania,et al.  Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. , 1995, The New England journal of medicine.

[10]  M. Chang,et al.  Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone. A randomized, digoxin-controlled study. , 1995, European heart journal.

[11]  F. Morady,et al.  Effect of atrial fibrillation on atrial refractoriness in humans. , 1996, Circulation.

[12]  Amit Kumar.  Intravenous Amiodarone for Therapy of Atrial Fibrillation and Flutter in Critically Ill Patients With Severely Depressed Left Ventricular Function , 1996, Southern medical journal.

[13]  M. Santini,et al.  Effects of oral propafenone administration before electrical cardioversion of chronic atrial fibrillation: a placebo-controlled study. , 1996, Journal of the American College of Cardiology.

[14]  M. Russo,et al.  Histological substrate of atrial biopsies in patients with lone atrial fibrillation. , 1997, Circulation.

[15]  K. Ellenbogen,et al.  Antiarrhythmic actions of intravenous ibutilide compared with procainamide during human atrial flutter and fibrillation: electrophysiological determinants of enhanced conversion efficacy. , 1997, Circulation.

[16]  G. Lip,et al.  Original papers , 2013 .

[17]  P C Deedwania,et al.  Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators. , 1998, Circulation.

[18]  J Clémenty,et al.  Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. , 1998, The New England journal of medicine.

[19]  F. Morady,et al.  Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment. , 1999, The New England journal of medicine.

[20]  S. Connolly.  Evidence-based analysis of amiodarone efficacy and safety. , 1999, Circulation.

[21]  Bramahn . Singh,et al.  Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens. , 1999, Journal of the American College of Cardiology.

[22]  A. Camm,et al.  Double-blind placebo-controlled trial of digoxin in symptomatic paroxysmal atrial fibrillation. , 1999, Circulation.

[23]  Management of new onset atrial fibrillation. , 2000, Evidence report/technology assessment.

[24]  A. Goette,et al.  Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. , 2000, Journal of the American College of Cardiology.

[25]  M. Santini,et al.  Comparison of intravenously administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter. A multicentre, randomized, double-blind, placebo-controlled study. , 2000, European heart journal.

[26]  A. Aggarwal.  Amiodarone to prevent recurrence of atrial fibrillation. , 2000, The New England journal of medicine.

[27]  C Antzelevitch,et al.  The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. , 2000, European heart journal.

[28]  Marlene R. Miller,et al.  The evidence regarding the drugs used for ventricular rate control. , 2000, The Journal of family practice.

[29]  P. Vardas,et al.  Amiodarone as a first-choice drug for restoring sinus rhythm in patients with atrial fibrillation: a randomized, controlled study. , 2000, Chest.

[30]  S. Hohnloser,et al.  Rhythm or rate control in atrial fibrillation—Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial , 2000, The Lancet.

[31]  F. Martínez-Marcos,et al.  Comparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm. , 2000, The American journal of cardiology.

[32]  J. McMurray,et al.  Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study , 2001, Heart.

[33]  M. Rich,et al.  Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. , 2001, JAMA.

[34]  D. Singer,et al.  Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. , 2001, JAMA.

[35]  I. Khan.  Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation. , 2001, Journal of the American College of Cardiology.

[36]  B. Gersh,et al.  Long-term survival after ablation of the atrioventricular node and implantation of a permanent pacemaker in patients with atrial fibrillation. , 2001, The New England journal of medicine.

[37]  Simon Stewart,et al.  A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. , 2002, The American journal of medicine.

[38]  E. Bernal,et al.  Use of Irbesartan to Maintain Sinus Rhythm in Patients With Long-Lasting Persistent Atrial Fibrillation: A Prospective and Randomized Study , 2002, Circulation.

[39]  A L Waldo,et al.  A comparison of rate control and rhythm control in patients with atrial fibrillation. , 2002, The New England journal of medicine.

[40]  Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation. A prospective and randomized study ☆ , 2002 .

[41]  B. Maron,et al.  Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. , 2002, Journal of the American College of Cardiology.

[42]  G. Breithardt,et al.  Anterior-posterior versus anterior-lateral electrode positions for external cardioversion of atrial fibrillation: a randomised trial , 2002, The Lancet.

[43]  H. Crijns,et al.  A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation , 2002 .

[44]  J. Brugada,et al.  Long-lasting sport practice and lone atrial fibrillation. , 2002, European heart journal.

[45]  H. Crijns,et al.  A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. , 2002, The New England journal of medicine.

[46]  J. Cleland,et al.  Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? , 2003, Journal of the American College of Cardiology.

[47]  Yuchiao Chang,et al.  Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? , 2003, JAMA.

[48]  U. Tebbe,et al.  Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. , 2003, Journal of the American College of Cardiology.

[49]  V. Santinelli,et al.  A randomized study of prophylactic catheter ablation in asymptomatic patients with the Wolff-Parkinson-White syndrome. , 2003, The New England journal of medicine.

[50]  Ying Wang,et al.  KCNQ1 gain-of-function mutation in familial atrial fibrillation. , 2003, Science.

[51]  Haran Burri,et al.  Amiodarone versus placebo and class Ic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis. , 2003, Journal of the American College of Cardiology.

[52]  M. Bulsara,et al.  The Australian Intervention Randomized Control of Rate in Atrial Fibrillation Trial (AIRCRAFT). , 2003, Journal of the American College of Cardiology.

[53]  Silvia G Priori,et al.  ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Co , 2003, Circulation.

[54]  Silvia G Priori,et al.  ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Co , 2003, Circulation.

[55]  Stefan Kääb,et al.  Sotalol testing unmasks altered repolarization in patients with suspected acquired long-QT-syndrome--a case-control pilot study using i.v. sotalol. , 2003, European heart journal.

[56]  Temporary Atrial Epicardial Pacing as Prophylaxis Against Atrial Fibrillation after Heart Surgery: , 2003, Journal of cardiovascular electrophysiology.

[57]  Yuchiao Chang,et al.  Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. , 2003, The New England journal of medicine.

[58]  Wen-Chung Yu,et al.  Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. , 2003, European heart journal.

[59]  Ralph B D'Agostino,et al.  Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring. , 2004, JAMA.

[60]  N. Smedira,et al.  Effectiveness of atrial fibrillation surgery in patients with hypertrophic cardiomyopathy. , 2004, The American journal of cardiology.

[61]  Theodor Landis,et al.  Usefulness of Ambulatory 7-Day ECG Monitoring for the Detection of Atrial Fibrillation and Flutter After Acute Stroke and Transient Ischemic Attack , 2004, Stroke.

[62]  G. Heinze,et al.  Flecainide versus ibutilide for immediate cardioversion of atrial fibrillation of recent onset. , 2004, European heart journal.

[63]  Prashanthan Sanders,et al.  Catheter ablation for atrial fibrillation in congestive heart failure. , 2004, The New England journal of medicine.

[64]  P. Alboni,et al.  Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach. , 2004, The New England journal of medicine.

[65]  G. Breithardt,et al.  Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. , 2004, European heart journal.

[66]  E. Daoud.  Management of atrial fibrillation in the post-cardiac surgery setting. , 2004, Cardiology clinics.

[67]  A. Torbicki,et al.  Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study. , 2004, Chest.

[68]  J. Mathew,et al.  A multicenter risk index for atrial fibrillation after cardiac surgery. , 2004, JAMA.

[69]  D. Levy,et al.  Lifetime Risk for Development of Atrial Fibrillation: The Framingham Heart Study , 2004, Circulation.

[70]  P. Vardas,et al.  Effects of Amiodarone and Diltiazem on Persistent Atrial Fibrillation Conversion and Recurrence Rates: A Randomized Controlled Study , 2004, Cardiovascular Drugs and Therapy.

[71]  S. Yusuf,et al.  Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery. , 2004, The Cochrane database of systematic reviews.

[72]  H. Crijns,et al.  Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation: A randomized, double-blind study , 1996, Cardiovascular Drugs and Therapy.

[73]  C. Israel,et al.  Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device: implications for optimal patient care. , 2004, Journal of the American College of Cardiology.

[74]  S. Yusuf,et al.  Clinical ResearchHeart Rhythm DisorderPrevention of Atrial Fibrillation With Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: A Meta-Analysis , 2005 .

[75]  D. Shah,et al.  Linear Cryoablation of the Left Atrium Versus Pulmonary Vein Cryoisolation in Patients With Permanent Atrial Fibrillation and Valvular Heart Disease: Correlation of Electroanatomic Mapping and Long-Term Clinical Results , 2005, Circulation.

[76]  S. Connolly,et al.  Effects of magnesium on atrial fibrillation after cardiac surgery: a meta-analysis , 2005, Heart.

[77]  Christopher Piorkowski,et al.  Perception of Atrial Fibrillation Before and After Radiofrequency Catheter Ablation: Relevance of Asymptomatic Arrhythmia Recurrence , 2005, Circulation.

[78]  Mandeep Bhargava,et al.  Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. , 2005, JAMA.

[79]  D. Reda,et al.  Amiodarone versus sotalol for atrial fibrillation. , 2005, The New England journal of medicine.

[80]  C. Fowler,et al.  Randomised evaluation of alternative electrosurgical modalities to treat bladder outflow obstruction in men with benign prostatic hyperplasia. , 2005, Health technology assessment.

[81]  H. Wellens.  When to Perform Catheter Ablation in Asymptomatic Patients With a Wolff-Parkinson-White Electrocardiogram , 2005, Circulation.

[82]  A. Skanes,et al.  Use of medications in Wolff-Parkinson-White syndrome , 2005, Expert opinion on pharmacotherapy.

[83]  J Raftery,et al.  A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study. , 2005, Health technology assessment.

[84]  M. Nieminen,et al.  Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. , 2005, Journal of the American College of Cardiology.

[85]  Linear Cryoablation of the Left Atrium Versus Pulmonary Vein Cryoisolation in Patients With Permanent Atrial Fibrillation and Valvular Heart Disease , 2005 .

[86]  Douglas L Packer,et al.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. , 2005, The New England journal of medicine.

[87]  Douglas Packer,et al.  Worldwide Survey on the Methods, Efficacy, and Safety of Catheter Ablation for Human Atrial Fibrillation , 2005, Circulation.

[88]  Jeffrey L. Anderson,et al.  Sodium channel mutations and susceptibility to heart failure and atrial fibrillation. , 2005, JAMA.

[89]  Dietrich Andresen,et al.  Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. , 2005, European heart journal.

[90]  Gregory Y H Lip,et al.  Quality of life in patients with atrial fibrillation: a systematic review. , 2006, The American journal of medicine.

[91]  Stephen S. Cha,et al.  Secular Trends in Incidence of Atrial Fibrillation in Olmsted County, Minnesota, 1980 to 2000, and Implications on the Projections for Future Prevalence , 2006, Circulation.

[92]  S. Mohiuddin,et al.  Meta-analysis: inhibition of renin-angiotensin system prevents new-onset atrial fibrillation. , 2006, American heart journal.

[93]  S. Bagshaw,et al.  Prophylactic amiodarone for prevention of atrial fibrillation after cardiac surgery: a meta-analysis. , 2006, The Annals of thoracic surgery.

[94]  Rahul Mehra,et al.  Comparison of continuous versus intermittent monitoring of atrial arrhythmias. , 2006, Heart rhythm.

[95]  D. Singer,et al.  Age and the Risk of Warfarin‐Associated Hemorrhage: The Anticoagulation and Risk Factors In Atrial Fibrillation Study , 2006, Journal of the American Geriatrics Society.

[96]  Jun Dong,et al.  Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation. , 2006, European heart journal.

[97]  Pietro Delise,et al.  Recommendations for participation in leisure-time physical activity and competitive sports in patients with arrhythmias and potentially arrhythmogenic conditions Part I: Supraventricular arrhythmias and pacemakers , 2006, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[98]  A. Keech,et al.  Interventions for prevention of post-operative atrial fibrillation and its complications after cardiac surgery: a meta-analysis. , 2006, European heart journal.

[99]  M. Pfeffer,et al.  Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. , 2006, American heart journal.

[100]  A. Hofman,et al.  Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. , 2006, European heart journal.

[101]  F. Van de Werf,et al.  Endurance sports is a risk factor for atrial fibrillation after ablation for atrial flutter. , 2006, International journal of cardiology.

[102]  M. Pfeffer,et al.  Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial , 2006, The Lancet.

[103]  V. Santinelli,et al.  A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: the APAF Study. , 2006, Journal of the American College of Cardiology.

[104]  J. Dunning,et al.  Guidelines on the prevention and management of de novo atrial fibrillation after cardiac and thoracic surgery. , 2006, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[105]  C. White,et al.  Safety of amiodarone in the prevention of postoperative atrial fibrillation: a meta-analysis. , 2006, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[106]  M. Pfeffer,et al.  Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial. , 2006, American heart journal.

[107]  Barry J Maron,et al.  Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interd , 2006, Circulation.

[108]  V. Pasceri,et al.  Randomized Trial of Atorvastatin for Reduction of Postoperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery: Results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) Study , 2006, Circulation.

[109]  Kiyoshi Yoshida,et al.  Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial. , 2006, Stroke.

[110]  J. Copeland,et al.  Amiodarone Prophylaxis for Atrial Fibrillation After Cardiac Surgery: Meta‐Analysis of Dose Response and Timing of Initiation , 2007, Pharmacotherapy.

[111]  J. Ruskin,et al.  HRS/EHRA/ECAS expert Consensus Statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on catheter and surgical ablation of atrial fibrillation. , 2007, Heart rhythm.

[112]  B. Gersh,et al.  Long-Term Progression and Outcomes With Aging in Patients With Lone Atrial Fibrillation: A 30-Year Follow-Up Study , 2007, Circulation.

[113]  D. Ngaage,et al.  Influence of preoperative atrial fibrillation on late results of mitral repair: is concomitant ablation justified? , 2007, The Annals of thoracic surgery.

[114]  M. Aguilar,et al.  Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation , 2007, Annals of Internal Medicine.

[115]  A. Tveit,et al.  Effect of candesartan and various inflammatory markers on maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation. , 2007, The American journal of cardiology.

[116]  Bertil Olsson,et al.  Outcome parameters for trials in atrial fibrillation: executive summary. , 2007, European heart journal.

[117]  J. Ruskin,et al.  HRS/EHRA/ECAS expert Consensus Statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on catheter and surgical ablation of atrial fibrillation. , 2007, Heart rhythm.

[118]  J. Le Heuzey,et al.  Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis. , 2007, European heart journal.

[119]  J. Camm,et al.  Is there any hope for angiotensin-converting enzyme inhibitors in atrial fibrillation? , 2007, American heart journal.

[120]  M. Metra,et al.  Long-term survival of patients with heart failure and ventricular conduction delay treated with cardiac resynchronization therapy. , 2007, The American journal of cardiology.

[121]  Helmut Baumgartner,et al.  Guidelines on the management of valvular heart disease The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology , 2007 .

[122]  G. Lip,et al.  Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial , 2007, The Lancet.

[123]  S. Mouly,et al.  Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. , 2007, The Cochrane database of systematic reviews.

[124]  David A Fitzmaurice,et al.  Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial , 2007, BMJ : British Medical Journal.

[125]  E. Aliot,et al.  Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. , 2007, The New England journal of medicine.

[126]  M. de Andrade,et al.  Atrial natriuretic peptide frameshift mutation in familial atrial fibrillation. , 2008, The New England journal of medicine.

[127]  E. Aliot,et al.  Delayed rhythm control of atrial fibrillation may be a cause of failure to prevent recurrences: reasons for change to active antiarrhythmic treatment at the time of the first detected episode. , 2007, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[128]  John V. Wylie,et al.  Catheter ablation vs antiarrhythmic drug therapy for atrial fibrillation: a systematic review. , 2008, Archives of internal medicine.

[129]  A. Camm,et al.  Vernakalant Hydrochloride for Rapid Conversion of Atrial Fibrillation: A Phase 3, Randomized, Placebo-Controlled Trial , 2008, Circulation.

[130]  A. Camm,et al.  Rhythm Control versus Rate Control for Atrial Fibrillation and Heart Failure , 2009 .

[131]  A. Zanchetti,et al.  Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial , 2008, Journal of hypertension.

[132]  Perry M. Elliott,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2010, European journal of heart failure.

[133]  G. Lip,et al.  Consensus document on antithrombotic therapy in the setting of electrophysiological procedures. , 2008, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[134]  A. Raviele,et al.  Antiarrhythmic Effect of Statin Therapy and Atrial Fibrillation A Meta-Analysis of Randomized Controlled Trials. , 2008, Journal of atrial fibrillation.

[135]  J. Davy,et al.  Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study. , 2008, American heart journal.

[136]  F. Sacher,et al.  Catheter Ablation Versus Antiarrhythmic Drugs for Atrial Fibrillation: The A4 Study , 2008, Circulation.

[137]  Gregory Y H Lip,et al.  Stroke and thromboembolism in atrial fibrillation: A systematic review of stroke risk factors, risk stratification schema and cost effectiveness data , 2008, Thrombosis and Haemostasis.

[138]  Curt D. Furberg,et al.  Physical Activity and Incidence of Atrial Fibrillation in Older Adults: The Cardiovascular Health Study , 2008, Circulation.

[139]  D. Wyse.  Pharmacotherapy for rhythm management in elderly patients with atrial fibrillation , 2009, Journal of Interventional Cardiac Electrophysiology.

[140]  Michael Böhm,et al.  Kommentar zu den ESC-Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 , 2008, European journal of heart failure.

[141]  Tong Liu,et al.  Statin use and development of atrial fibrillation: a systematic review and meta-analysis of randomized clinical trials and observational studies. , 2008, International journal of cardiology.

[142]  G. Breithardt,et al.  Atrial fibrillation in stroke-free patients is associated with memory impairment and hippocampal atrophy. , 2008, European heart journal.

[143]  J. Camm,et al.  Statins and polyunsaturated fatty acids for treatment of atrial fibrillation , 2008, Nature Clinical Practice Cardiovascular Medicine.

[144]  M. Metra,et al.  Long-term survival in patients undergoing cardiac resynchronization therapy: the importance of performing atrio-ventricular junction ablation in patients with permanent atrial fibrillation , 2008, European heart journal.

[145]  David O. Martin,et al.  Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. , 2008, The New England journal of medicine.

[146]  A. Gillinov,et al.  Surgical approaches for atrial fibrillation. , 2008, The Medical clinics of North America.

[147]  J. McMurray,et al.  Increased mortality after dronedarone therapy for severe heart failure. , 2008, The New England journal of medicine.

[148]  L. Fauchier,et al.  Antiarrhythmic effect of statin therapy and atrial fibrillation a meta-analysis of randomized controlled trials. , 2008, Journal of the American College of Cardiology.

[149]  J. Molnar,et al.  Prevention of Atrial Fibrillation by Way of Abrogation of the Renin-Angiotensin System: A Systematic Review and Meta-Analysis , 2008, American journal of therapeutics.

[150]  J. Hirsh,et al.  Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.

[151]  D. Singer,et al.  Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.

[152]  Jagmeet P. Singh,et al.  Cardiac resynchronization in patients with atrial fibrillation: a meta-analysis of prospective cohort studies. , 2008, Journal of the American College of Cardiology.

[153]  S. Mittal,et al.  Long‐Term Outcome Following Successful Pulmonary Vein Isolation: Pattern and Prediction of Very Late Recurrence , 2008, Journal of cardiovascular electrophysiology.

[154]  S. Hohnloser,et al.  Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. , 2009, European heart journal.

[155]  E. Aliot,et al.  Indications for the use of diagnostic implantable and external ECG loop recorders. , 2009, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[156]  A. Goette,et al.  Acute atrial tachyarrhythmia induces angiotensin II type 1 receptor-mediated oxidative stress and microvascular flow abnormalities in the ventricles , 2009, European heart journal.

[157]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[158]  M. Hirai,et al.  Optimal treatment strategy for patients with paroxysmal atrial fibrillation: J-RHYTHM Study. , 2009, Circulation journal : official journal of the Japanese Circulation Society.

[159]  Douglas Packer,et al.  Prevalence and causes of fatal outcome in catheter ablation of atrial fibrillation. , 2009, Journal of the American College of Cardiology.

[160]  Matthew R. Reynolds,et al.  Treatment of Atrial Fibrillation With Antiarrhythmic Drugs or Radiofrequency Ablation: Two Systematic Literature Reviews and Meta-Analyses , 2009, Circulation. Arrhythmia and electrophysiology.

[161]  Salim Yusuf,et al.  Effect of clopidogrel added to aspirin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[162]  Maurice Buchbinder,et al.  Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial , 2009, The Lancet.

[163]  S. Perlini,et al.  Prevention of recurrent lone atrial fibrillation by the angiotensin-II converting enzyme inhibitor ramipril in normotensive patients. , 2009, Journal of the American College of Cardiology.

[164]  I. Savelieva,et al.  Primary and secondary prevention of atrial fibrillation with statins and polyunsaturated fatty acids: review of evidence and clinical relevance , 2010, Naunyn-Schmiedeberg's Archives of Pharmacology.

[165]  E. Toft,et al.  Vernakalant Hydrochloride for the Rapid Conversion of Atrial Fibrillation After Cardiac Surgery: A Randomized, Double-Blind, Placebo-Controlled Trial , 2009, Circulation. Arrhythmia and electrophysiology.

[166]  A. Skanes,et al.  Validation of a New Simple Scale to Measure Symptoms in Atrial Fibrillation: The Canadian Cardiovascular Society Severity in Atrial Fibrillation Scale , 2009, Circulation. Arrhythmia and electrophysiology.

[167]  Paulus Kirchhof,et al.  Can we improve outcomes in AF patients by early therapy? , 2009, BMC medicine.

[168]  N. Freemantle,et al.  Morbidity and Mortality Associated With Anti-Arrhythmic Drugs in Atrial Fibrillation: A Systematic Review and Mixed Treatment Meta-Analysis , 2009 .

[169]  G. Wassmer,et al.  Statins for prevention of atrial fibrillation after cardiac surgery: a systematic literature review. , 2009, The Journal of thoracic and cardiovascular surgery.

[170]  T. Arora,et al.  Reversal of propoxur-induced impairment of memory and oxidative stress by 4′-chlorodiazepam in rats , 2009, Naunyn-Schmiedeberg's Archives of Pharmacology.

[171]  P. Kirchhof,et al.  Giant T-U waves precede torsades de pointes in long QT syndrome: a systematic electrocardiographic analysis in patients with acquired and congenital QT prolongation. , 2009, Journal of the American College of Cardiology.

[172]  F. Regoli,et al.  Cardiac resynchronization therapy in heart failure patients with atrial fibrillation , 2009, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[173]  G. Breithardt,et al.  The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management , 2008, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[174]  Stephan Willems,et al.  Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference 'research perspectives in AF'. , 2009, European heart journal.

[175]  J. Healey,et al.  A Systematic Review of Randomized Trials Comparing Radiofrequency Ablation with Antiarrhythmic Medications in Patients with Atrial Fibrillation , 2009, Journal of cardiovascular electrophysiology.

[176]  C. Gieger,et al.  A sequence variant in ZFHX3 on 16q22 associates with atrial fibrillation and ischemic stroke , 2009, Nature Genetics.

[177]  Timothy Watson,et al.  Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited , 2009, The Lancet.

[178]  G. Naccarelli,et al.  Increasing prevalence of atrial fibrillation and flutter in the United States. , 2009, The American journal of cardiology.

[179]  A. Rigby,et al.  A randomised, controlled study of rate versus rhythm control in patients with chronic atrial fibrillation and heart failure: (CAFÉ-II Study) , 2009, Heart.

[180]  Nancy R Cook,et al.  Relation of vigorous exercise to risk of atrial fibrillation. , 2009, The American journal of cardiology.

[181]  A. Maggioni,et al.  Valsartan for prevention of recurrent atrial fibrillation. , 2009, The New England journal of medicine.

[182]  S. Connolly,et al.  Effect of dronedarone on cardiovascular events in atrial fibrillation. , 2009, The New England journal of medicine.

[183]  V. Hasselblad,et al.  Pulmonary Vein Isolation for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation: A Meta-Analysis of Randomized, Controlled Trials , 2009, Circulation. Arrhythmia and electrophysiology.

[184]  K. Ho,et al.  Benefits and Risks of Corticosteroid Prophylaxis in Adult Cardiac Surgery: A Dose-Response Meta-Analysis , 2009, Circulation.

[185]  M. Rosenqvist,et al.  Atorvastatin and persistent atrial fibrillation following cardioversion: a randomized placebo-controlled multicentre study. , 2008, European heart journal.

[186]  G. Lip,et al.  Identifying Patients at High Risk for Stroke Despite Anticoagulation: A Comparison of Contemporary Stroke Risk Stratification Schemes in an Anticoagulated Atrial Fibrillation Cohort , 2010, Stroke.

[187]  J. Sturdivant,et al.  Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial , 2010 .

[188]  R. Vest.  Comparative Efficacy of Dronedarone and Amiodarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation , 2010 .

[189]  Jeroen J. Bax,et al.  Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery , 2009 .

[190]  D. Arnar,et al.  Does treatment with n-3 polyunsaturated fatty acids prevent atrial fibrillation after open heart surgery? , 2010, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[191]  M. Böhm,et al.  Prevention of Atrial Fibrillation by Renin-Angiotensin System Inhibition , 2010 .

[192]  J. Le Heuzey,et al.  A Short‐Term, Randomized, Double‐Blind, Parallel‐Group Study to Evaluate the Efficacy and Safety of Dronedarone versus Amiodarone in Patients with Persistent Atrial Fibrillation: The DIONYSOS Study , 2010, Journal of cardiovascular electrophysiology.

[193]  P. Kirchhof,et al.  Management of Antithrombotic Therapy in Atrial Fibrillation Patients Presenting with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention/ Stenting , 2009, Thrombosis and Haemostasis.

[194]  Otto Kamp,et al.  Lenient versus strict rate control in patients with atrial fibrillation. , 2010, The New England journal of medicine.

[195]  Burr Hall,et al.  Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. , 2010, JAMA.

[196]  S. Kaul,et al.  Dronedarone for atrial fibrillation have we expanded the antiarrhythmic armamentarium? , 2010, Journal of the American College of Cardiology.

[197]  S. Connolly,et al.  Maintenance of sinus rhythm and survival in patients with heart failure and atrial fibrillation. , 2010, Journal of the American College of Cardiology.

[198]  W. W. Brabham.  Valsartan for Prevention of Recurrent Atrial Fibrillation , 2010 .

[199]  M. Cheitlin.  Comparison of Beta Blocker and Digoxin Alone and in Combination for Management of Patients With Atrial Fibrillation and Heart Failure , 2010 .

[200]  Jeroen J. Bax,et al.  Prediction of atrial fibrillation in patients with an implantable cardioverter‐defibrillator and heart failure , 2010, European journal of heart failure.

[201]  M. Rosenqvist,et al.  Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation. , 2010, European heart journal.

[202]  Gregory Y H Lip,et al.  Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. , 2010, Chest.

[203]  D. Tamborero,et al.  Efficacy of circumferential pulmonary vein ablation of atrial fibrillation in endurance athletes , 2009, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[204]  Gerhard Hindricks,et al.  Performance of a New Leadless Implantable Cardiac Monitor in Detecting and Quantifying Atrial Fibrillation Results of the XPECT Trial , 2010, Circulation. Arrhythmia and electrophysiology.

[205]  L. Køber,et al.  Excessive Supraventricular Ectopic Activity and Increased Risk of Atrial Fibrillation and Stroke , 2010, Circulation.

[206]  F. Crea,et al.  Usefulness of statins in preventing atrial fibrillation in patients with permanent pacemaker: a systematic review. , 2010, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[207]  P. Calder,et al.  Omega-3 Fatty Acid Supplementation Does Not Reduce Risk of Atrial Fibrillation After Coronary Artery Bypass Surgery: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial , 2010, Circulation. Arrhythmia and electrophysiology.

[208]  Elia Biganzoli,et al.  Updated Worldwide Survey on the Methods, Efficacy, and Safety of Catheter Ablation for Human Atrial Fibrillation , 2005, Circulation. Arrhythmia and electrophysiology.

[209]  H. Wiste,et al.  Atrioventricular nodal ablation predicts survival benefit in patients with atrial fibrillation receiving cardiac resynchronization therapy. , 2010, Heart rhythm.

[210]  P. Kirchhof,et al.  Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. , 2011, Physiological reviews.

[211]  A. Capucci,et al.  A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. , 2011, Journal of the American College of Cardiology.

[212]  Robby Nieuwlaat,et al.  Revised A novel user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: The Euro Heart Survey , 2012 .

[213]  Rimm,et al.  Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. , 2001, The New England journal of medicine.